Abstract. Objective: To determine the safety and effectiveness of intravenous (IV) etomidate for the sedation of patients undergoing painful procedures in the emergency department (ED). Methods: A twopart feasibility study for ED patients receiving IV etomidate for painful ED procedures was undertaken. In the initial phase, a retrospective series of patients receiving etomidate for ED procedural sedation was considered. This phase served as the basis for a descriptive, prospective feasibility study of consecutive ED patients. During the second phase, patients were evaluated for complications related to IV etomidate sedation or the procedure performed. Immediately following the procedure, the physician was asked to complete a data collection sheet documenting the patient's etomidate dose, the number of doses required to complete the procedure, the analgesic used, the complications of the procedure, and the patient's procedural recall. Results: Intravenous etomidate was administered to nine patients during the initial study phase and 51 during the prospective, descriptive phase. Indications for sedation included dislocation reduction (25), cardioversion (7), fracture reduction (20), abscess incision and drainage (4), foreign body removal (3), and chest thoracostomy (1). Physicians used 0.1-mg/kg IV bolus etomidate. A mean of 1.6 doses of etomidate was used to complete procedures (range 1-3 doses). Of the 60 patients in both study groups, 59 (98%) achieved adequate sedation by physician's assessment. Procedural success was documented for 56 patients (93%). There were 12 complications reported: oxygen desaturation below 90% (5), myoclonus (4), vomiting (1), pain with injection (1), and a brief bradycardic episode (1). No patient required assistance with ventilation or endotracheal intubation. Conclusions: Intravenous etomidate can be administered safely and effectively to provide appropriate conscious sedation for short, painful ED procedures. Key words: etomidate; sedation; conscious sedation; emergency department procedures. ACA-DEMIC EMERGENCY MEDICINE 2001; 8:13-18 E TOMIDATE is an imidazole hypnotic agent commonly used for emergent intravenous (IV) induction preceding endotracheal intubation. Its use in this setting continues to gain favor among emergency physicians (EPs), who value its rapid onset of action, short duration of sedation, and minimal respiratory and hemodynamic effects. A recent survey evaluating intubation practices at U.S. academic emergency departments (EDs) documented etomidate as the preferred induction agent in 23% of surveyed EDs. Patients who undergo painful procedures in the ED often require sedation and muscle relaxation for short periods. The strengths that are cited for the use of etomidate as an induction agent would infer value as a sedative agent. However, to the best of our knowledge, etomidate has received little attention within the context of procedural sedation. [2][3][4][5][6] In the setting of emergent procedural sedation, the shorter duration of action of etomidate relat...
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.